ZimVie — Q3 2024 Earnings Presentation
15 slides from ZimVie's earnings presentation, Oct 30, 2024
Slide 1: A Global Dental Leader
A Global Dental Leader October 2024 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans
Slide 3: ZimVie: A Global Dental Leader
ZimVie: A Global Dental Leader Powerful, market-leading portfolio of premium implants, restorative implant solutions, biomaterials solutions, and digital dentistry technologies 8 Million 8 million U.S. patients seek treatment for tooth loss annually 25% Only 25% receive tooth replacement Focused on
Slide 4: Clear Strategy for Value Creation
Clear Strategy for Value Creation Completed sale of spine business in April 2024 Paid down $275M of debt, significantly improving balance sheet health Reducing corporate overhead, IT and legal costs following sale of spine business Optimizing manufacturing operations through automation Aligning glob
Slide 5: Dental Implants: Portfolio Overview
Dental Implants: Portfolio Overview Premium implant portfolio catering to both routine and complex cases along with a full range of abutments, copings, and analogs Key Products & Brands TSX® Implant Launched in 2022, TSX Implants are designed to simplify procedures and optimize practice protocols to
Slide 6: Biomaterials: Portfolio Overview
Biomaterials: Portfolio Overview Biomaterial solutions that are used for soft tissue and bone rehabilitation, helping build sufficient bone necessary for dental implant surgery Key Products & Brands Barrier Membranes By providing a reliable barrier during the critical phases of wound healing, these
Slide 7: Digital Dentistry: Portfolio Overview
Digital Dentistry: Portfolio Overview End-to-end solutions ranging from intraoral scanning technology to open architecture CAD/CAM systems, guided surgery solutions, and patient-specific restorations Key Products & Brands GenTek™ System End-to-end prosthetic offerings designed to support CAD/CAM res
Slide 8: Revitalizing the Portfolio with Recent Launches
Revitalizing the Portfolio with Recent Launches T3® PRO Implant Encode® Emergence Healing Abutment TSX® Implant Azure™ Multi-Platform Solutions Portfolio RegenerOss® Cortico–Cancellous Particulate RegenerOss® Bone Graft Plug Biotivity™ A/C Plus Membrane RealGUIDE® 5.4 Software CAD/CAM Workflow Syste
Slide 9: End-to-End Solutions Save Time and Improve the Clinician and Patient Experience
Virtual Treatment Planning Custom Surgical Guide Kits Delivering digital workflow enhancements to save clinician time and improve patient satisfaction AI facilitated reconstruction procedures require 3 fewer hours of human labor* ZimVie Encode Emergence workflow reduces chair time and saves one rest
Slide 10: Financial Profile & Outlook
Financial Profile & Outlook Net Sales Adjusted EBITDA Q3 2024* FY 2024 $103.2M $13.1M(1) $450M-$455M $60M-$62M(2) Drivers of Progress Expanding portfolio adoption within large, underserved dental markets Reducing expense profile to improve margins Best-in-class portfolio and commitment to ongoing in
Slide 11: Committed to Executing Strategic Transformation
Committed to Executing Strategic Transformation Commercialize new product introductions across major geographies Drive digital workflow adoption to expand implant adoption Address and reduce stranded costs Optimize manufacturing & supply chain capabilities Position the business for sustainable growt
Slide 12: Appendix
Dp Appendix < ZimVie
Slide 13: Note on Non-GAAP Financial Measures
Note on Non-GAAP Financial Measures This presentation includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by
Slide 14: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA Continuing Operations ($ in thousands) [1] Restructuring activities to better position our organization for future success based on the current business environment and sale of the spine business. [2] Acquisition, integration, divestiture and related expenses for th
Slide 15: Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS
Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS Continuing Operations (in thousands, except per share data) [1] Restructuring activities to better position the organization and the expenses incurred were primarily related to severance and professional fees. [2] Acquisition, integration